Genetically Informed Smoking Cessation Trial

基因知情戒烟试验

• 批准号: 8929203
• 负责人: Li-Shiun Chen
• 金额: $ 68.3万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8929203
• 关键词: Abstinence; Address; Adherence; Adverse effects; Adverse event; Algorithms; Biological Markers; Carbon Monoxide; Cessation of life; Clinical; Clinical Treatment; Combination Medication; Counseling; Data; Dependence; Development; Ensure; Equilibrium; Failure; Genes; Genetic; Genetic Markers; Genetic Models; Genetic Variation; Genotype; Goals; Grouping; Health; Heart; Hybrids; Individual; Intervention; Link; Lung diseases; Measures; Meta-Analysis; Metabolism; Methods; Modeling; Nausea; Nicotine; Nicotine Dependence; Nicotinic Receptors; Other Genetics; Outcome; Participant; Patient Care; Patients; Pharmaceutical Preparations; Pharmacogenetics; Pharmacotherapy; Physicians; Placebo Control; Placebos; Principal Investigator; Randomized; Receptor Gene; Recommendation; Reporting; Research; Risk; Risk Factors; Severities; Side; Smoke; Smoker; Smoking; Socioeconomic Status; Testing; Time; Translations; Trees; Variant; Withholding Treatment; Work; base; cancer prevention; cost; cytochrome P-450 CYP2A6 (human); design; disability; evidence base; follow-up; genetic predictors; head-to-head comparison; improved; innovation; medication compliance; modifiable risk; mortality; nicotine replacement; non-genetic; personalized medicine; primary outcome; prospective; randomized trial; response; smoking cessation; success; trial design; varenicline

DESCRIPTION (provided by applicant): Our overarching goal is to determine whether genetic markers can be used to optimize smoking cessation pharmacotherapy to enhance efficacy, medication adherence, and reduce side effects. Smoking is a leading cause of preventable death and disability, and smoking cessation reverses the risk of mortality. However, cessation failure is common despite available cessation medications, which are associated with different efficacy, side effects, adherence, use constraints, and costs. This challenge can be addressed by improving current treatments via personalized medicine based on individual genetic markers to maximize efficacy and minimize side effects. Our recent work suggesting that the nicotinic receptor gene CHRNA5 alters response to nicotine replacement therapy (NRT) has been replicated in a meta-analysis. Our new preliminary data suggest that CHRNA5 may be a useful marker for medication choice, because patients with CHRNA5 variant rs16969968 AA/GA genotypes may benefit from NRT and those with GG genotypes (conferring poor response to NRT) may benefit from varenicline, a medication with higher cost and use restrictions. Similarly, other genetic variation such as the nicotine metabolism gene CYP2A6 also alters response to NRT. Currently there is insufficient evidence to support the clinical use of genotype based smoking cessation treatment, because these findings are based on retrospective pharmacogenetic analyses of different trials with markedly different placebo and counseling effect sizes and dissimilar designs. For clinical translation, we need head to head comparison of state-of-the-art interventions, use of key genotypes implicated by current research, and valid assessments of side effects/ adherence. We propose a first, prospective, genotype-based stratified randomization trial to compare the two most effective smoking cessation medications (combination NRT [patch and lozenge], varenicline vs. placebo for 3 months) in 720 smokers with known genotypes. Leveraging the Principal Investigator's observational genetic follow-up study of smoking cessation with existing genotypes, this study uses a stratified randomization trial design based on a subject's pertinent genotype for smoking cessation. Specifically, in Aim 1, we will determine if CHRNA5 genotype moderates the effect of medication (combination NRT, varenicline, vs. placebo) on abstinence. In Aim 2, we will determine if CHRNA5 genotype predicts medication adherence and side effects. In Aim 3, we will incorporate multiple genotypes and other predictors in order to develop a clinical treatment assignment algorithm for cessation success. This proposal is an innovative smoking cessation trial leveraging existing genotyped smokers and a genotype-based randomization design to build the evidence base to support a genotype based algorithm that can optimize smoking cessation pharmacotherapy in terms of efficacy, side effects, adherence, and improve overall smoking cessation success. This work can result in improved physician care of patients who smoke, overall smoking cessation success, and prevention of cancer, heart, and lung disease.

描述(由申请人提供)：我们的首要目标是确定是否可以使用遗传标记来优化戒烟药物治疗，以提高疗效、药物依从性和减少副作用。吸烟是可预防的死亡和残疾的主要原因，戒烟可以逆转死亡风险。然而，尽管有戒烟药物，但戒烟失败仍然很常见，这些药物与不同的疗效、副作用、依从性、使用限制和成本有关。这一挑战可以通过基于个体遗传标记的个性化药物改进当前的治疗方法来解决，以最大限度地提高疗效并将副作用降至最低。我们最近的工作表明，尼古丁受体基因CHRNA5改变了尼古丁替代疗法(NRT)的反应，这一结果在荟萃分析中得到了复制。我们新的初步数据表明，CHRNA5可能是一个有用的药物选择标记物，因为CHRNA5变异rs16969968 AA/GA基因型的患者可能受益于NRT，而那些对NRT反应较差的GG基因型患者可能受益于Varenicline，这是一种成本较高、使用限制较高的药物。同样，尼古丁代谢基因CYP2A6等其他基因变异也会改变对NRT的反应。目前没有足够的证据支持基于基因的戒烟治疗的临床应用，因为这些发现是基于对不同试验的回溯性药物遗传学分析，这些试验具有明显不同的安慰剂和咨询效果大小和不同的设计。对于临床翻译，我们需要对最先进的干预措施进行面对面的比较，使用当前研究所涉及的关键基因类型，并对副作用/依从性进行有效评估。我们提出了一项基于基因的前瞻性分层随机试验，以比较两种最有效的戒烟药物(联合使用NRT[贴片和含片]、varenicline与安慰剂，为期3个月)在720名已知基因的吸烟者中的疗效。利用首席调查员对戒烟的观察性遗传随访研究，本研究采用分层随机试验设计，基于受试者与戒烟相关的基因。具体地说，在目标1中，我们将确定CHRNA5基因是否缓和药物(联合NRT、varenicline和安慰剂)对禁欲的影响。在目标2中，我们将确定CHRNA5基因是否预测药物依从性和副作用。在目标3中，我们将结合多种基因类型和其他预测因素，以开发一种戒烟成功的临床治疗分配算法。这项建议是一项创新的戒烟试验，利用现有的基因分型吸烟者和基于基因的随机设计来建立证据基础，以支持基于基因的算法，该算法可以在疗效、副作用、依从性方面优化戒烟药物治疗，并提高整体戒烟成功率。这项工作可以改善吸烟患者的医生护理，总体上戒烟成功，并预防癌症、心脏病和肺病。